Gibson Dunn has advised Galecto, Inc. Cooley LLP has advised the underwriters. Goodwin Procter LLP acted as intellectual property counsel for Galecto, Inc. Galecto, Inc. (Nasdaq:...
Galecto Closes $316 Million Public Offering of Common Stock
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering
Gibson Dunn has represented Cogent Biosciences, Inc., and Mintz has advised the underwriters. Cogent Biosciences, Inc. (Nasdaq: COGT) has announced the pricing of its underwritten public...
Galecto Acquires Damora Therapeutics and Secures $285 Million PIPE Investment
Cleary Gottlieb has advised Viking Global Investors. Gibson Dunn has advised Damora Therapeutics. The acquisition of Damora Therapeutics Inc. by Galecto Inc. was completed alongside a...
Dianthus Therapeutics Closes $288 Million Public Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
Spyre Therapeutics’ $200 Million Common Stock Offering
Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
GlycoMimetics’ Acquisition of Crescent Biopharma
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...